Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Alvine Pharmaceuticals logo — Pioneering solutions for autoimmune and gastrointestinal hea...

Alvine Pharmaceuticals

Pioneering solutions for autoimmune and gastrointestinal health with a promising treatment for celiac disease through innovative gluten-digesting technology

Founded 2005 1 employees Debt Financing Total: $68.01M Biotechnology, Health and Wellness +1

General Information

Company Name Alvine Pharmaceuticals
Founded Year 2005
Founders / Decision Makers
Team member
Employees 1
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Alvine Pharmaceuticals. To contact Alvine Pharmaceuticals, visit alvinepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Alvine Pharmaceuticals compare?

A PDF of Alvine Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Alvine Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Alvine Pharmaceuticals

Alvine Pharmaceuticals is a privately held biopharmaceutical company established in 2005, with a focus on providing innovative treatments for autoimmune and gastrointestinal diseases. The company's flagship product, ALV003, is a groundbreaking combination protease intended to break down gluten, targeting patients with celiac disease. With a slogan of "Pioneering solutions for autoimmune and gastrointestinal health," Alvine Pharmaceuticals demonstrates a strong commitment to developing cutting-edge technologies in the biotechnology, health and wellness, and pharmaceutical industries. The company successfully secured a $6.01M Debt Financing investment on 03 January 2013, reflecting the confidence of investors in its potential to address unmet medical needs. This investment further underscores the company's promising trajectory in providing solutions for prevalent health challenges.

Business keywords: Biopharmaceutical, Autoimmune Diseases, Gastrointestinal Health, Celiac Disease Treatment, Gluten-digesting Technology, Therapeutics, Innovative Treatments, Drug Development, Medical Research, Private Company, ALV003 Product, Protease Therapy, Healthcare Innovation, Clinical Trials

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $6.01M -
03 Jan 2013
Debt Financing $6.01M -
21 Oct 2011
Venture Round $26.50M -
10 Mar 2011
Series A $21.50M 6
InterWest Partners Prospect Venture Partners Flagship Pioneering
InterWest Partners, Prospect Venture Partners +4
11 Sep 2006
Series A $8.00M 2
Prospect Venture Partners Sofinnova Investments
Prospect Venture Partners, Sofinnova Investments
06 Sep 2006

Alvine Pharmaceuticals Alternatives & Competitors

View All Alternatives
Alvine Pharmaceuticals vs
Anthera Pharmaceuticals
Anthera Pharmaceuticals

Pioneering Therapeutics to Combat Inflammatory Diseases, Pioneering Better Health

Post-IPO Equity
Biotechnology, Health Care
Alvine Pharmaceuticals vs
ImmusanT
ImmusanT

Pioneering advancements for celiac disease through innovative diagnostics and therapeutic solutions

Venture round
Biotechnology, Health Care
Alvine Pharmaceuticals vs
Telormedix
Telormedix

Pioneering targeted immunity for cancer and autoimmune disease treatment through innovative biopharm...

Series B
Biopharma, Biotechnology
View all alternatives

FAQ About Alvine Pharmaceuticals

Pioneering solutions for autoimmune and gastrointestinal health with a promising treatment for celiac disease through innovative gluten-digesting technology
Alvine Pharmaceuticals was founded in 2005.
Alvine Pharmaceuticals operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Biopharmaceutical, Autoimmune Diseases, Gastrointestinal Health and Celiac Disease Treatment.
Alvine Pharmaceuticals has approximately 1 employees.
Alvine Pharmaceuticals has completed 5 funding rounds, raising a total of $68.01M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Alvine Pharmaceuticals include Anthera Pharmaceuticals, ImmusanT, Telormedix, Proclara Biosciences, Applied Immune Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alvine Pharmaceuticals and Anthera Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Alvine Pharmaceuticals, https://bouncewatch.com/company/alvine-pharmaceuticals, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout